Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Long-Term Deferred Tax: 2018-2019

  • Akebia Therapeutics' Long-Term Deferred Tax fell 3.04% to $109.4 million in Q4 2019 from the same period last year, while for Dec 2019 it was $109.4 million, marking a year-over-year decrease of 3.04%. This contributed to the annual value of $109.4 million for FY2019, which is 3.04% down from last year.
  • Akebia Therapeutics' Long-Term Deferred Tax amounted to $109.4 million in Q4 2019, which was down 3.04% from $112.8 million recorded in Q4 2018.
  • Over the past 5 years, Akebia Therapeutics' Long-Term Deferred Tax peaked at $112.8 million during Q4 2018, and registered a low of $109.4 million during Q4 2019.
  • For the 2-year period, Akebia Therapeutics' Long-Term Deferred Tax averaged around $111.1 million, with its median value being $111.1 million (2018).
  • Data for Akebia Therapeutics' Long-Term Deferred Tax shows a maximum YoY fell of 3.04% (in 2019) over the last 5 years.
  • Akebia Therapeutics' Long-Term Deferred Tax (Quarterly) stood at $112.8 million in 2018, then declined by 3.04% to $109.4 million in 2019.